National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Commissioned Corps, US Public Health Service, Atlanta, Georgia.
JAMA Psychiatry. 2021 Apr 1;78(4):372-379. doi: 10.1001/jamapsychiatry.2020.4402.
The coronavirus disease 2019 (COVID-19) pandemic, associated mitigation measures, and social and economic impacts may affect mental health, suicidal behavior, substance use, and violence.
To examine changes in US emergency department (ED) visits for mental health conditions (MHCs), suicide attempts (SAs), overdose (OD), and violence outcomes during the COVID-19 pandemic.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the Centers for Disease Control and Prevention's National Syndromic Surveillance Program to examine national changes in ED visits for MHCs, SAs, ODs, and violence from December 30, 2018, to October 10, 2020 (before and during the COVID-19 pandemic). The National Syndromic Surveillance Program captures approximately 70% of US ED visits from more than 3500 EDs that cover 48 states and Washington, DC.
Outcome measures were MHCs, SAs, all drug ODs, opioid ODs, intimate partner violence (IPV), and suspected child abuse and neglect (SCAN) ED visit counts and rates. Weekly ED visit counts and rates were computed overall and stratified by sex.
From December 30, 2018, to October 10, 2020, a total of 187 508 065 total ED visits (53.6% female and 46.1% male) were captured; 6 018 318 included at least 1 study outcome (visits not mutually exclusive). Total ED visit volume decreased after COVID-19 mitigation measures were implemented in the US beginning on March 16, 2020. Weekly ED visit counts for all 6 outcomes decreased between March 8 and 28, 2020 (March 8: MHCs = 42 903, SAs = 5212, all ODs = 14 543, opioid ODs = 4752, IPV = 444, and SCAN = 1090; March 28: MHCs = 17 574, SAs = 4241, all ODs = 12 399, opioid ODs = 4306, IPV = 347, and SCAN = 487). Conversely, ED visit rates increased beginning the week of March 22 to 28, 2020. When the median ED visit counts between March 15 and October 10, 2020, were compared with the same period in 2019, the 2020 counts were significantly higher for SAs (n = 4940 vs 4656, P = .02), all ODs (n = 15 604 vs 13 371, P < .001), and opioid ODs (n = 5502 vs 4168, P < .001); counts were significantly lower for IPV ED visits (n = 442 vs 484, P < .001) and SCAN ED visits (n = 884 vs 1038, P < .001). Median rates during the same period were significantly higher in 2020 compared with 2019 for all outcomes except IPV.
These findings suggest that ED care seeking shifts during a pandemic, underscoring the need to integrate mental health, substance use, and violence screening and prevention services into response activities during public health crises.
2019 年冠状病毒病(COVID-19)大流行、相关缓解措施以及社会和经济影响可能会影响心理健康、自杀行为、药物使用和暴力。
研究 COVID-19 大流行期间美国急诊部(ED)就诊的心理健康状况(MHC)、自杀未遂(SA)、过量(OD)和暴力结局的变化。
设计、设置和参与者:这项横断面研究使用了疾病控制与预防中心国家综合征监测计划的数据,以检查从 2018 年 12 月 30 日至 2020 年 10 月 10 日(COVID-19 大流行之前和期间)期间 MHC、SA、OD 和暴力的 ED 就诊全国变化。国家综合征监测计划从美国 3500 多家覆盖 48 个州和华盛顿特区的 ED 中捕获了大约 70%的 ED 就诊量。
结果测量是 MHC、SA、所有药物 OD、阿片类药物 OD、亲密伴侣暴力(IPV)和疑似儿童虐待和忽视(SCAN)ED 就诊次数和就诊率。按性别分层计算了总体和每周 ED 就诊次数和就诊率。
从 2018 年 12 月 30 日至 2020 年 10 月 10 日,共捕获了 187508065 次总 ED 就诊量(53.6%为女性,46.1%为男性);6018318 次就诊至少包括 1 项研究结果(就诊不互斥)。自 2020 年 3 月 16 日美国开始实施 COVID-19 缓解措施以来,ED 就诊量总体减少。从 2020 年 3 月 8 日至 28 日,所有 6 项结果的每周 ED 就诊次数均减少(3 月 8 日:MHC=42903,SA=5212,所有 OD=14543,阿片类药物 OD=4752,IPV=444,SCAN=1090;3 月 28 日:MHC=17574,SA=4241,所有 OD=12399,阿片类药物 OD=4306,IPV=347,SCAN=487)。相反,从 2020 年 3 月 22 日至 28 日,ED 就诊率开始上升。当 2020 年 3 月 15 日至 10 月 10 日的中位数 ED 就诊次数与 2019 年同期进行比较时,2020 年的就诊次数明显更高:SA(n=4940 与 4656,P=0.02)、所有 OD(n=15604 与 13371,P<0.001)和阿片类药物 OD(n=5502 与 4168,P<0.001);IPV ED 就诊(n=442 与 484,P<0.001)和 SCAN ED 就诊(n=884 与 1038,P<0.001)次数较低。同期的中位数率在 2020 年明显高于 2019 年,除了 IPV。
这些发现表明,在大流行期间 ED 护理寻求发生转变,这突显出需要在公共卫生危机期间将心理健康、药物使用和暴力筛查和预防服务纳入应对活动中。